Answers are grounded in this paper and cite their sources.
To the Editor: The DESTINY-Breast04 trial showed that patients whose tumors test negative for protein overexpression or gene amplification of human epidermal growth factor receptor 2 (HER2) can benefit from delivery of a targeted cytotoxic payload by trastuzumab deruxtecan. 1 Semiquantitative immunohistochemical (IHC) assays lack the accuracy to measure lower levels of HER2, 2 and excluding patients with IHC 0 results from that trial was unwarranted. 3 The members of the American Society of Clinical Oncology–College of American Pathologists (ASCO–CAP) HER2 Testing Guideline Panel understood the practical need to more clearly distinguish IHC 1+ results from IHC 0 results. 2 However, absent evidence of . . .
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: